Autopsy report · NCT06524739

Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

“Sponsor decision, not for safety reasons.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 10 months before it stopped.
• 16 participants enrolled.
• Results were posted on the registry 9 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

CSL Behring

Sponsor type

Industry

Conditions

Post-COVID Postural Orthostatic Tachycardia Syndrome

Interventions

IgPro20; Placebo

Participants

16

Sites

38

Countries

Canada, United States

Trials that died the same way

• Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
  “Sponsor decision not related to safety reasons” (92% match in meaning)
• A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause
  “Sponsor decision; Not a safety decision” (92% match in meaning)
• (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
  “Sponsor decision, not related to safety concerns” (92% match in meaning)
• NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
  “sponsor decision (not for safety)” (91% match in meaning)
• A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts
  “Sponsor decision, not safety related” (91% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.